Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VERTEX PHARMACEUTICALS INC / MA Director's Dealing 2018

Jan 23, 2018

29864_dirs_2018-01-23_bf0f3f36-9420-474b-b2f8-3a5d004be12c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2018-01-19

Reporting Person: Sachdev Amit (EVP, CRO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-01-19 Common Stock M 18672 $77.31 Acquired 57835 Direct
2018-01-19 Common Stock M 13750 $83.36 Acquired 71585 Direct
2018-01-19 Common Stock S 18410 $157.67 Disposed 53175 Direct
2018-01-19 Common Stock S 13312 $158.59 Disposed 39863 Direct
2018-01-19 Common Stock S 700 $159.35 Disposed 39163 Direct
2018-01-22 Common Stock M 13750 $83.36 Acquired 52913 Direct
2018-01-22 Common Stock S 13750 $160.00 Disposed 39163 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-01-19 Stock Option (Right to Buy) $77.31 M 18672 Disposed 2024-02-04 Common Stock (18672) Direct
2018-01-19 Stock Option (Right to Buy) $83.36 M 13750 Disposed 2023-07-29 Common Stock (13750) Direct
2018-01-22 Stock Option (Right to Buy) $83.36 M 13750 Disposed 2023-07-29 Common Stock (13750) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 882 Indirect
Common Stock 12215 Indirect

Footnotes

F1: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $157.67 (range $157.18 to $158.17).

F3: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $158.59 (range $158.20 to $159.10).

F5: Open market sales reported on this line occurred at a weighted average price of $159.35 (range $159.27 to $159.45).

F6: Reflects a change in the form of ownership resulting from transfers of shares between a trust and Mr. Sachdev.

F7: The option vests in 16 quarterly installments from 2/5/2014.

F8: Fully vested.